Form 8-K - Current report:
SEC Accession No. 0001213900-24-090150
Filing Date
2024-10-24
Accepted
2024-10-24 09:03:47
Documents
22
Period of Report
2024-10-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0218458-8k_elevai.htm   iXBRL 8-K 33248
2 RESULTS OF EFFICACY STUDY OF NEW DRUG CANDIDATE FOR SARCOPENIA ea021845801ex99-1_elevai.htm EX-99.1 5825
3 PRESS RELEASE DATED OCTOBER 21, 2024 ea021845801ex99-2_elevai.htm EX-99.2 15215
4 GRAPHIC ex99-1_001.jpg GRAPHIC 132408
5 GRAPHIC ex99-1_002.jpg GRAPHIC 334805
6 GRAPHIC ex99-1_003.jpg GRAPHIC 295760
7 GRAPHIC ex99-1_004.jpg GRAPHIC 483362
8 GRAPHIC ex99-1_005.jpg GRAPHIC 426759
9 GRAPHIC ex99-1_006.jpg GRAPHIC 499924
10 GRAPHIC ex99-1_007.jpg GRAPHIC 257224
  Complete submission text file 0001213900-24-090150.txt   3585204

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE elab-20241021.xsd EX-101.SCH 3033
12 XBRL LABEL FILE elab-20241021_lab.xml EX-101.LAB 34240
13 XBRL PRESENTATION FILE elab-20241021_pre.xml EX-101.PRE 22371
24 EXTRACTED XBRL INSTANCE DOCUMENT ea0218458-8k_elevai_htm.xml XML 3795
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

EIN.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241390875
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)